Characteristics and clinical correlates of restless legs syndrome in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 5, 2007, Pages 1078-1083

  Kang, Seung Gul ^a   Lee, Heon Jeong ^a,b   Jung, Sung Won ^c   Cho, Sung Nam ^c   Han, Changsu ^a   Kim, Yong Ku ^a   Kim, Seung Hyun ^a   Lee, Min Soo ^a   Joe, Sook Haeng ^a   Jung, In Kwa ^a   Kim, Leen ^a  

^a College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Bugok National Hospital   (South Korea)

Author keywords

Insomnia; Psychiatric symptom; Restless legs syndrome; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; PREVALENCE; RATING SCALE; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SEX; STATISTICAL SIGNIFICANCE;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP;

EID: 34249324437     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.03.011     Document Type: Article

References (33)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7 (2004) S1-S5
2. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide (letter). Arch Neurol 39 (1982) 739
3. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 5 (2004) 385-391
4. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., and Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless leg syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 4 (2003) 101-119
5. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia (1997), American Psychiatric Press, Washington, DC
6. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 154 (1989) 672-676
7. Bazire S. Psychotropic drug directory. The professionals' pocket handbook and aide memoire (2005), Fivepin, Salisbury UK
8. Bjorvatn B., Leissner L., Ulfberg J., Grying J., Karlsborg M., Regeur L., et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 6 (2005) 307-312
9. Brown E.E., Nomikos G.G., Wilson C., and Fibiger H.C. Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 202 (1991) 125
10. Damsa C., Bumb A., Bianchi-Demicheli F., Vidailhet P., Sterck R., Andreoli A., et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 65 (2004) 1064-1068
11. Hales R.E., and Yudofsky S.C. Textbook of clinical psychiatry. 4th ed (2002), American Psychiatric Publishing, Washington, DC
12. Hornyak M., Kopasz M., Berger M., Riemann D., and Voderholzer U. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry 66 (2005) 1139-1145
13. Inagaki A., Inada T., Fujii Y., Yagi G., Yoshio T., Nakamura H., et al. Dose equivalence of psychotic drugs (1999), Seiwa Press, Tokyo not available in English
14. Kim J.Y., Choi C., Shin K., Yi H., Park M., Cho N., et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry Clin Neurosci 59 (2005) 350-353
15. Kryger M.H., Roth T., and Dement W.C. Principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Philadelphia
16. Mateos J.J., Lomena F., Parellada E., Font M., Fernandez E., Pavia J., et al. Decreased striatal dopamine transporter binding assessed with [1231] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181 (2005) 401-406
17. Mateos J.J., Lomena F., Parellada E., Mireia M., Fernandez-Egea E., Pavia J., et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 191 (2007) 805-811
18. Michaud M., Soucy J.P., Chabli A., Lavigne G., and Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 249 (2002) 164-170
19. Mizuno S., Miyaoka T., Inagaki T., and Horiguchi J. Prevalence of restless legs syndrome in non-institutionalized Japanese elderly. Psychiatry Clin Neurosci 54 (2005) 461-465
20. Montplaisir J., Nicolas A., Denesle R., and Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52 (1999) 938-943
21. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep 10 (1962) 799-812
22. Overall J.E., Hollister L.E., and Pichot P. Major psychiatric disorders. A four-dimensional model. Arch Gen Psychiatry 16 (1967) 146-151
23. Phillips B., Young T., Finn L., Asher K., Hening W.A., and Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 160 (2000) 2137-2141
24. Richard B.B. Sleep medicine pearls. 2nd ed (2003), Elsevier's Health Sciences Rights, Philadelphia
25. Ruottinen H.M., Partinen M., Hublin C., Bergman J., Haaparanta M., Solin O., et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 54 (2000) 502-504
26. Scavone C., Aizenstein M.L., Planeta Cda S., and De Lucia R. Long-term effects of imipramine on striatal dopamine autoreceptor function: involvement of both noradrenergic and scrotonergic systems. Gen Pharmacol 23 (1992) 397
27. Soldatos C.R., Dikeos D.G., and Paparrigopoulos T.J. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res 55 (2003) 263-267
28. Turjanski N., Lees A.J., and Brooks D.J. Striatal dopaminergic receptor dysfunction in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52 (1999) 932-937
29. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
30. Wetter T.C., Stiasny K., Winkelmann J., Buhlinger A., Brandenburg U., Penzel T., et al. A randomized, controlled study of pergolide in patients with restless legs syndrome. Neurology 52 (1999) 944-950
31. Winkelmann J., Schadrack J., Wetter T.C., Zieglgansberger W., and Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med 2 (2001) 57-61
32. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
33. Wunderlich G.R., Evans K.R., Sills T., Pollentier S., Reess J., Allen R.P., et al. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 6 (2005) 131-139